Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition
- PMID: 3485688
Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition
Abstract
We have demonstrated that immune complexes turn over C1, i.e., limiting quantities of immune complexes activate an excess of C1. This was readily apparent in a system of purified C1 and C1-inhibitor (C1-In) but not in normal human serum (NHS). The following results indicate that C3 and C4 are the serum factors responsible for the inhibition of C1 turnover by immune complexes. 1) In a purified protein system composed of C1 and C1-In at pH 7.5, ionic strength 0.14 M, doses of immune complexes that activated all the C1 in 60 min at 37 degrees C yielded no detectable C1 activation when C2, C3, and C4 were also present. All proteins were at their physiologic concentrations. Activation was quantified by SDS-PAGE analysis and hemolytic titration 2) In order to inactivate C3 and C4, NHS was treated with 50 mM methylamine (MeAm) for 15 min at 37 degrees C, after which the MeAm was removed by dialysis. The activities of C1, C2, and C1-In were unaffected by this treatment. Doses of immune complexes that consumed no C1 in NHS, consumed all the C1 in MeAm-treated NHS (MeAm-NHS). 3) Reconstitution of MeAm-NHS with physiologic concentrations of C3 and C4 rendered the serum again resistant to excessive C1 consumption by immune complexes. Immune complexes used in these studies included EA-IgG, EA-IgM, tetanus-human anti-tetanus, and aggregated human IgG. There appeared to be specificity to the inhibition reaction since C4 by itself could inhibit C1 consumption by EA-IgM, whereas the presence of C3 was also required to control EA-IgG. Finally, N-acetyl-L-tyrosine was added to NHS at a final concentration of 30 mM. This nucleophile did not interact with native C3 or C4, nor did it directly activate C1. However, upon the addition of low doses of immune complexes, acetyl tyrosine did yield uncontrolled C1 activation, presumably by binding nascent C3b and C4b and thereby blocking their attachment to the immune complexes. We conclude that in NHS there is a mechanism of feedback inhibition by which nascent C3b and C4b inhibit C1 turnover by immune complexes. This mechanism of control might be physiologically important in that it prevents excessive complement activation by low concentrations of immune complexes.
Similar articles
-
Inhibition of immune precipitation by complement.J Immunol. 1984 Sep;133(3):1464-70. J Immunol. 1984. PMID: 6747294
-
Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.J Immunol. 1983 Jul;131(1):403-8. J Immunol. 1983. PMID: 6602833
-
Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.Cancer Res. 1993 Feb 1;53(3):592-9. Cancer Res. 1993. PMID: 8425193
-
Control of immune complexes by the classical pathway.Behring Inst Mitt. 1989 Jul;(84):111-20. Behring Inst Mitt. 1989. PMID: 2529842 Review.
-
An affinity for complement C3 as a possible reason for the potency of naturally occurring antibodies in mediating tissue homeostasis.Beitr Infusionsther. 1989;24:193-9. Beitr Infusionsther. 1989. PMID: 2481539 Review.
Cited by
-
Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).Mol Immunol. 2006 Feb;43(3):236-45. doi: 10.1016/j.molimm.2005.02.004. Epub 2005 Mar 5. Mol Immunol. 2006. PMID: 16199260 Free PMC article.
-
C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.Immunology. 1998 Dec;95(4):648-54. doi: 10.1046/j.1365-2567.1998.00635.x. Immunology. 1998. PMID: 9893058 Free PMC article.
-
Cloning and sequencing of full-length cDNA encoding the precursor of human complement component C1r.Biochem J. 1986 Dec 15;240(3):783-7. doi: 10.1042/bj2400783. Biochem J. 1986. PMID: 3030286 Free PMC article.
-
Dominant role of splenic marginal zone lipid rafts in the classical complement pathway against S. pneumoniae.Cell Death Discov. 2019 Sep 9;5:133. doi: 10.1038/s41420-019-0213-3. eCollection 2019. Cell Death Discov. 2019. PMID: 31531231 Free PMC article.
-
C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.Biochem J. 1989 Feb 1;257(3):831-8. doi: 10.1042/bj2570831. Biochem J. 1989. PMID: 2784671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous